Fumiko Tamura
Fumiko Tamura is associate manager, GSK, CMC Regulatory Affairs, Tokyo, Japan
Articles
Risk-Based Intermediate Precision Studies for Analytical Procedure Validation
September 15th 2019Validation of analytical procedures require assessment of the impact of variations within laboratories; however, guidance to study intermediate precision has been lacking. Science and risk-based principles should be used in the design of intermediate precision studies.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: October 28th 2024 | Updated: November 21st 2024
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Published: November 6th 2024 | Updated: November 21st 2024
Automate Aseptic Filling: Closing the System at Full Modularity
Published: November 5th 2024 | Updated: November 21st 2024
Untethered Data: Unifying and Contextualizing Drug Discovery Data
Published: November 8th 2024 | Updated: November 21st 2024
Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification
